Neutral
Pfizer stock holds steady at $27.72 amid FDA approval of updated COVID-19 vaccine
Pfizer's stock price remained stable at $27.72 following the FDA's approval of its updated COVID-19 vaccine for the 2026-2027 season. The vaccine targets the XFG variant, with shipments beginning immediately. Analysts maintain a consensus "Hold" rating with an average price target of $28.28.
Key points
- FDA approves Pfizer's updated COVID-19 vaccine for 2026-2027 season.
- Analysts maintain "Hold" rating with average price target of $28.28.
- Pfizer's stock price remains steady at $27.72.
Sources
AI-generated from public news sources. Not financial advice.
